Earnings call transcript: UiPath tops revenue forecast in Q2 2026, shares slide

UiPath reported Q2 FY2027 revenue of $410.26M (up 13% YoY) versus the $397.77M forecast (+3.14%), with adjusted EPS of $0.15 in line, but the stock fell 9.77% to $16.44 in after-hours (from a $18.24 close), signaling investor concern about forward growth and valuation. The quarter showed improving scale with ARR rising 12% YoY to $1.938B and GAAP operating income of $32M (fourth straight GAAP profitable quarter), with 18 of the top 20 deals including AI. Guidance for Q3 calls for revenue of $440M–$445M and ARR of $1.992B–$1.997B, while full-year revenue is forecast at $1.789B–$1.794B and non-GAAP operating income around $445M.

Analysis

The market is signaling that PATH’s problem is not execution, it is conversion: investors still need proof that AI is monetizing into sustained net new ARR rather than just enlarging deal size. The next leg is likely driven less by the quarter itself and more by whether management can show a cleaner path from pilot wins to repeatable consumption at the Sept. 22 Investor Day; until then, the stock can stay range-bound as “AI attach rate” is not the same as durable growth acceleration.

Second-order, the mix shift toward larger enterprises is a double-edged sword. It improves retention and pricing power, but it also raises concentration risk and lengthens sales cycles, which makes guidance inherently conservative and leaves the equity more exposed to any slip in a handful of large deals. The rising use of coding agents should help services partners and implementation capacity, but it can also compress the economic moat if customers perceive deployment becoming faster and more interchangeable.

The contrarian miss on the tape is that the bear case is not AI commoditization alone; it is that PATH may be moving from a broad land-grab to a narrower, higher-friction platform sale before the AI product stack is fully monetized. Over 1-3 months, the important watch item is whether Q3 ARR lands above the guide and whether the company can defend >109% net retention while shrinking small-customer attrition. If not, the post-earnings de-rating can extend; if yes, the setup becomes a re-rating story into a cleaner FY27 bridge.

Key Decisions for Investors

• Wait for the Sept. 22 Investor Day before adding risk; use any reflex bounce in PATH toward the pre-earnings range to initiate a small short or buy put spreads, targeting a 1-2 month window where proof of AI monetization is still incomplete.
• Pair trade: short PATH / long MSFT over 1-3 months. If enterprise buyers are standardizing around governance + agentic workflows, the platform winner with distribution and suite leverage should outperform the standalone automation vendor.
• For a higher-conviction event trade, buy PATH Nov-Dec downside put spreads only if management fails to show ARR acceleration or gives cautious commentary on transaction/outcome pricing adoption; the thesis breaks if Q3 ARR prints at or above the top end of guide and FY27 ARR is raised.
• Watch the next two catalysts: Q3 ARR guide execution and customer concentration metrics. A sustained move above $18 with improving net new ARR would falsify the short thesis; a drop back below the post-earnings low after Investor Day would confirm the market is discounting a slower monetization curve.